| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 國家衛生研究院 |
2012-05-20 |
Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial
|
Poon, RTP;Chen, LT;Xue, HL;Tannir, B;Wang, JH;Tanwandee, T;Paik, SW |
| 國立成功大學 |
2007 |
Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma
|
Chiou, Tzeon-Jye; Wang, Teng-Hsu; Chao, Tsu-Yi; Lin, Sheng-Fung; Tang, Jih-Luh; Chen, Tsai-Yun; Chang, Ming-Chih; Hsueh, Erh-Jung; Chen, Po-Min |
| 國立臺灣大學 |
2007 |
Randomized Phase Ii Trial of Thalidomide Alone Versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma
|
邱宗傑; 趙祖怡; 林勝豐; 唐季祿; 陳彩雲; 張明志; 薛爾榮; 陳博明; CHIOU, TZEON-JYE; CHAO, TSU-YI; LIN, SHENG-FONG; TANG, JIH-LUH; CHEN, TSAI-YUN; CHANG, MING-CHIH; HSUEH, ERH-JUNG; CHEN, PO-MIN |
| 臺大學術典藏 |
2021-01-06T03:58:49Z |
Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma
|
Chiou T.-J.; Wang T.-H.; Chao T.-Y.; Lin S.-F.; JIH-LUH TANG; Chen T.-Y.; Chang M.-C.; Hsueh E.-J.; Chen P.-M. |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
|
Kojima T.;Shah M.A.;Muro K.;Francois E.;Adenis A.;Chih-Hung Hsu;Doi T.;Moriwaki T.;Kim S.-B.;Lee S.-H.;Bennouna J.;Kato K.;Shen L.;Enzinger P.;Qin S.-K.;Ferreira P.;Chen J.;Girotto G.;De La Fouchardiere C.;Senellart H.;Al-Rajabi R.;Lordick F.;Wang R.;Suryawanshi S.;Bhagia P.;Peter Kang S.;Metges J.-P.;Keynote-181 Investigators; Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators |
| 臺大學術典藏 |
2021-01-12T12:53:45Z |
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
|
Spicka I.; Ocio E.M.; Oakervee H.E.; Greil R.; Banh R.H.; SHANG-YI HUANG; D?�Rozario J.M.; Dimopoulos M.A.; Martínez S.; Extremera S.; Kahatt C.; Alfaro V.; Carella A.M.; Meuleman N.; Hájek R.; Symeonidis A.; Min C.-K.; Cannell P.; Ludwig H.; Sonneveld P.; Mateos M.V. |
| 國立臺灣大學 |
2005 |
Randomized Phase Iii Study of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma with Curative Resection - the Taiwan Cooperative Oncology Group (Tcog T1297) Study
|
李伯皇; 鄭隆賓; 陳培哲; LEE, PO-HUANG; JENG, LONG-BIN; CHEN, PEI- JER |
| 國立臺灣大學 |
2005-10 |
Randomized phase III study of adjuvant interferon alfa-2B in hepatocellular carcinoma with curative resection - The Taiwan cooperative oncology group (TCOG T1297) study
|
Chen, LT; Chen, MF; Lee, LA; Lee, PH; Jeng, LB; Lin, DY; Wu, CC; Mok, KT; Chen, CL; Lee, WC; Chau, GY; Chen, YS; Lui, WY; Chen, PJ |
